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Abstract
Context: There is insufficient knowledge about the chondrocyte membranome and its
molecular composition.
Objective: To develop a Triton X-114 based separation technique using nanoLC-MS/MS
combined with shotgun proteomics to identify chondrocyte membrane proteins.
Materials and methods: Articular chondrocytes from equine metacarpophalangeal joints were
separated into hydrophobic and hydrophilic fractions; trypsin-digested proteins were analysed
by nanoLC-MS/MS.
Results: A total of 315 proteins were identified. The phase extraction method yielded a high
proportion of membrane proteins (56%) including CD276, S100-A6 and three VDAC isoforms.
Discussion: Defining the chondrocyte membranome is likely to reveal new biomarker targets for
conventional and biological drug discovery.
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Introduction
Proteins that are embedded in or associated with biological
membranes play critically important roles in a wide range of
vital cellular functions including transport, cell–cell commu-
nication and signalling processes. As the plasma membrane
(PM) acts as the first barrier to the extracellular environment,
PM proteins enable cells to sense and respond to external
stimuli in a specific manner – they include receptors; cell
recognition, cell–cell or cell–matrix adhesion sites; enzymes;
as well as channels, pores and transporters for ions, small
molecules and nutrients (Cordwell & Thingholm, 2010).
Based on domain predictions by different methods, membrane
proteins comprise approx. 15–30% of the human proteome
(Almen et al., 2009; Kabbani, 2008), highlighting the funda-
mental importance of membrane-associated physiological
processes. PM proteins are also the primary targets of many
of the drugs that are currently in our pharmaceutical arsenal;
indeed, the majority (over 70%) of currently marketed drugs
act on PM proteins (Almen et al., 2009; Rabilloud, 2003). The
qualitative and quantitative composition of the PM proteome
is known to be significantly altered during cellular differen-
tiation and disease. Membrane proteins have the potential to be
selective and sensitive biomarkers for disease progression and
prognosis. Furthermore, membrane proteins that exhibit
altered expression in disease states could be suitable candi-
dates for the development of sensitive receptor-targeted
imaging agents for non-invasive monitoring of biological
and inflammatory processes (Dissoki et al., 2015; Samkoe
et al., 2014; Sega & Low, 2008). Therefore, there is a critical
need for the development of tools and technologies for
identification and characterisation of membrane proteins to
complement physiological methods for elucidating their
functions. This combined approach will promote the discovery
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of new and better drugs, and the development of novel
treatment strategies of diseases.
Integral membrane proteins have an amphiphilic structure;
apart from hydrophilic domains located on the external
cytosolic or organellar surfaces, they also contain hydrophobic
(membrane-spanning) regions that directly interact with the
lipid bilayer of the membranes in which they are embedded.
High-resolution and high-throughput proteomic techniques
have been widely applied to study the PM proteome of various
cell types [for a review please see Cordwell & Thingholm
(2010)]. However, there are serious (mainly technical) limi-
tations that currently hinder advances in this field. In addition
to their very low relative abundance, their amphiphilic nature
and poor solubility makes membrane proteins challenging to
purify, identify and characterise on a proteomic scale. The use
of non-ionic detergents (e.g. the Triton X series in which the
number of hydrophilic oxyethylene units attached to the
hydrophobic octylphenyl residue determines the specific
physicochemical properties) has enabled the solubilisation
and characterisation of these proteins. Their use is based on the
principle that water-soluble proteins, unlike amphiphilic
membrane proteins, show little or no interaction with these
compounds; consequently, only integral membrane proteins
form mixed micelles with non-ionic detergents (Bordier,
1981). The cloud point, the temperature at which phase
separation occurs between the detergent and the aqueous
phase, is at approximately 20 C for Triton X-114, which
makes its application particularly convenient in studies aimed
at analysing integral membrane proteins (Bordier, 1981;
English et al., 2012; Mathias et al., 2011).
In addition to the application of non-ionic detergents, a
number of other approaches have been developed over the past
decades for the selective enrichment of membrane proteins
including precipitation and gradient centrifugation, biotinyla-
tion and affinity enrichment or the application of glycopro-
teomics [reviewed in Cordwell & Thingholm (2010)]. The
main technical challenge remaining in the analysis of integral
membrane subproteomes, however, is the ability to obtain high
purity membrane protein samples without the presence of high
abundance contaminating proteins from the cytoplasm or other
intracellular organelles. Comprehensive analyses of the
membrane protein complement (also known as the membra-
nome) of distinct cell types are relatively scarce; this can at
least partially be attributed to the challenges and limitations
described above. It is particularly true for chondrocytes, the
single cell type in articular cartilage that serves as a
specialised load-bearing tissue with unique tribological
properties such as a low-friction gliding surface and peculiar
rheology in synovial joints. The extracellular matrix (ECM)
of hyaline cartilage, in which chondrocytes are embedded,
primarily consists of a meshwork of type II collagen fibres
and other minor collagens (types VI, IX and XI); large
aggregating proteoglycans (e.g. aggrecan) and their constitu-
ent glycosaminoglycans (GAGs); as well as high quantities
of osmotically bound water (approx. 70% of the net weight
of ECM) and counteracting cations attracted by the net
negative charge of GAGs (Archer & Francis-West, 2003).
Because of its avascular nature and the inability of mature
chondrocytes to divide in situ, once damaged, articular
cartilage seldom regenerates on its own. Therefore, lesions
due to either osteoarthritis (OA) or traumatic injuries are
associated with progressive degeneration of articular cartil-
age, pain and disability. OA is still an unresolved clinical
problem, and developing novel therapies or drug targets
poses a major challenge (Mobasheri, 2013).
In order to identify proteins involved in pathological
processes affecting the structure and function of articular
cartilage such as OA, it is first necessary to characterise the
normal protein complement of chondrocytes in healthy
tissues. For proteomic studies, cartilage is very challenging
as the chondrocyte, its sole cell type, forms only 1–2% of the
volume of the tissue (Lambrecht et al., 2010). Although the
proteome of healthy (Lambrecht et al., 2010; Ruiz-Romero
et al., 2005) and OA-affected chondrocytes (Lambrecht et al.,
2008; Ruiz-Romero et al., 2008; Tsolis et al., 2015), as well as
the secretory profile (secretome) of a cartilage tissue explant
model of OA (Williams et al., 2013) has been published, the
‘‘hidden’’ proteome, i.e. low-abundance membrane proteins
or other poorly soluble proteins may have remained undis-
covered in those studies. Here, we report a technique for
profiling integral membrane proteins in primary equine
articular chondrocytes using an optimised Triton X-114
phase partitioning technique and LC-MS/MS analysis for
protein identification. To the best of our knowledge, this work
represents the first and most comprehensive analysis of the
integral membrane subproteome in chondrocytes reported.
This technique allowed us to establish CD276, S100-A6
(calcyclin) and three VDAC isoforms as key components of
the chondrocyte membranome.
Materials and methods
Isolation and culture of primary equine articular
chondrocytes
Articular chondrocytes were isolated from equine articular
cartilage. The animal used in this study was euthanized in a
UK-based abattoir for research-unrelated purposes, and
stunned before slaughter in accordance with Welfare of
Animals (Slaughter or Killing) Regulations 1995. Ethical
approval for the use of abattoir-derived animal tissues was
obtained from the Ethics Committee of the School
of Veterinary Science and Medicine, University of
Nottingham, with input from members of the University
of Nottingham Animal Welfare and Ethical Review Body
(AWERB). After opening the metacarpophalangeal joint
cavity under aseptic conditions and rinsing the articular
cartilage surface with sterile physiological saline, articular
cartilage shavings were taken from the distal end of the
metacarpal bone using a sterile surgical blade and placed in
serum-free DMEM (Thermo Fisher Scientific, Inc., Waltham,
MA) supplemented with 4% Penicillin/Streptomycin solution
(P/S, Sigma-Aldrich, St. Louis, MO) pre-warmed to 37 C as
described previously (Williams et al., 2013). The shavings
(100mm thick, 5 mm in diameter) were taken from the
superficial part of macroscopically normal cartilage areas
without any visible signs of degeneration, including discol-
ouration, fibrillation and surface irregularities, to avoid the
deep (calcified) layers of articular cartilage or the cartilage–
bone interface. The surface of articular cartilage did not
receive treatment prior to sampling to preserve the lamina
DOI: 10.3109/1354750X.2015.1130191 Membrane biomarkers in chondrocytes 573
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splendens (the uppermost surface layer of articular cartilage)
(Dunham et al., 1988).
Cartilage shavings were washed three times with sterile
PBS containing 10% P/S. Articular chondrocytes were
isolated by overnight incubation with 0.1% type II collagenase
(from Clostridium histolyticum; Invitrogen, Carlsbad, CA)
dissolved in serum-free DMEM containing 4% P/S solution at
37 C. Following dissociation of cartilage shavings by tritur-
ation the solution was filtered through a 70-mm nylon mesh
filter to yield a single cell suspension, and centrifuged at
800g for 5 min at room temperature. After washing twice in
serum-free DMEM, cells were resuspended in DMEM
containing 10% foetal calf serum (FCS; Invitrogen) and 2%
P/S solution, seeded into tissue culture flasks (Nunc; Thermo
Fisher Scientific), and cultured in a CO2 incubator at 37
C.
Cells were subcultured when they reached approx. 80%
confluency. The media was changed on every second day.
Cells from the second passage were used for further
experiments. A schematic overview of the experimental
design is shown in Figure 1.
Sample preparation, phase partitioning using triton
X-114, and methanol/chloroform extraction
Approximately 80% confluent cultures of primary equine
articular chondrocytes from passage 2 were washed with PBS,
then 2 mL of PBS containing 80 mL of protease inhibitor
cocktail (25, Sigma-Aldrich) was added to the flasks. The
flasks were placed on ice, and cells were liberated using a cell
scraper (Greiner, Stonehouse, UK). The solution was
centrifuged (at 850g for 2 min, room temperature), and
the pellet was resuspended in 600 mL of PBS containing 24 mL
of 25 protease inhibitor cocktail. After incubating on ice for
15 min, the suspension was transferred into a glass homogen-
iser and the cells were lysed.
Following the addition of Triton X-114 (Sigma-Aldrich) at
a final concentration of 0.75%, the lysate was incubated on ice
Figure 1. Schematic overview of the experi-
mental design used in this study.
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for 30 min with vortexing every 5 min. After centrifugation
(30 min, 10 000g, 4 C) the supernatant was retained and
incubated at 37 C for 5 min, and then on ice for 15 min. The
sample was centrifuged again (30 min, 10 000g, 4 C) and
the supernatant was incubated at 37 C for 5 min. Following
centrifugation for 3 min (1000g, room temperature), two
layers appeared. The upper layer (aqueous phase) contained
the hydrophilic proteins, the lower layer (detergent phase)
contained the hydrophobic proteins. To maximise the recov-
ery of membrane proteins, the upper layer was extracted
further by adding Triton X-114 at a final concentration of
0.75% and the phase partitioning procedure was repeated.
Finally, the two lower layers were combined together to
constitute the hydrophobic fraction, and the upper layer was
treated as the hydrophilic fraction.
To remove Triton X-114 from the samples, four times
the sample volume of methanol (Thermo Fisher Scientific)
was added to both fractions. After centrifugation at 15 000g
for 10 s at room temperature, two times the original
sample volume of chloroform (Sigma-Aldrich) was added.
The mixture was centrifuged again, and after adding three
times the original sample volume of HPLC grade water, the
sample was centrifuged for 5 min (15 000g, room tempera-
ture). The proteins accumulated at the interface between the
two layers formed during the last centrifugation step.
Following removal of the upper layer, three times the
sample volume of methanol was added, and after spinning
for 5 min (15 000g, 4 C), the pellet containing the proteins
was retained and air-dried.
Quantification of proteins
After methanol/chloroform extraction, the pellets were
dissolved in sample resuspension buffer containing 4% SDS
(Bio-Rad Laboratories, Inc., Hercules, CA), 0.2 M Tris pH
7.4 (Bio-Rad) and 0.15 M NaOH (Thermo Fisher Scientific).
Protein concentration in the samples was determined using
the Bio-Rad DC Protein Assay Kit according to the manu-
facturer’s protocol (Bio-Rad). The absorbance of the assayed
samples at 655 nm was read using a Bio-Rad Benchmark
Microplate Reader.
Polyacrylamide gel electrophoresis (SDS–PAGE)
Loading buffer containing 4Laemmli buffer and 3 M
dithiothreitol (DTT; Bio-Rad) was added to each sample
(typically, 4.8 mL 4Laemmli buffer and 1.2 mL 3M DTT was
added to 18 mL sample resuspension buffer), and then proteins
were fractionated by SDS–PAGE on a 12% polyacrylamide
gel. Proteins were initially run at 32 mA constant current, and
once the dye front reached the bottom of the stacking gel, the
current was increased to 45 mA. Protein bands were visualised
by silver staining using a Hoefer Processor Plus automated gel
stainer (Amersham, GE Healthcare Life Sciences, UK). The
protocol for silver staining was performed as described
previously (Yan et al., 2000).
Preparation and trypsin digestion of proteins for
LC-MS/MS analysis: in-solution digestion
The protein pellets from the methanol/chloroform extraction
step were resuspended in a solution of 50 mM ammonium
bicarbonate (AMBIC) (Sigma-Aldrich) and 10 mM DTT
(Bio-Rad), and incubated at 37 C for 30 min, vortexing
every 10 min. Following the addition of iodoacetamide (IAA,
Bio-Rad) at a final concentration of 55 mM, samples were
incubated at 37 C for 45 min in dark. Then, 1.2 mL of –20 C
acetone was added to each sample, and after mixing, the
samples were incubated at 4 C overnight. Protein precipitates
were pelleted by centrifugation at 15 000g for 5 min at 4 C.
Pellets were air-dried for 1 min, and then resuspended
in 20 mL of trypsin buffer including 50 mM AMBIC and
10 ng/mL Trypsin Gold (Promega, Madison, WA). Samples
were vortexed until the pellets were fully dissolved and then
incubated at 37 C for 16 h. Finally, 1 mL of formic acid (1%)
was added to each sample to stop the reaction. Samples were
stored at –80 C until analysis.
LC-MS/MS analysis
Samples were injected into a 15 cm C18 Pepmap column
using a Bruker (Coventry, UK) Easy-nanoLC UltiMate
(Bruker, Coventry, UK) 3000 RSLCnano chromatography
platform with a flow rate of 300 nL/min to separate peptides.
Three microlitres of each sample was injected into the HPLC
column. After peptide binding and washing processes on the
column, the complex peptide mixture was separated and
eluted by a gradient of solution A (100% water + 0.1% formic
acid) and solution B (100% ACN + 0.1% formic acid) over
115 min, followed by column washing and re-equilibration.
The peptides were delivered to a Bruker (Coventry, UK)
amaZon ETD ion trap instrument (Bruker, Coventry, UK).
The top five most intense ions from each MS scan were
selected for fragmentation. The nanoLC-MS/MS analysis was
performed three times on the samples (all triplicates).
Peptide and protein identification, data analysis and
bioinformatics
Processed data were compiled into *.MGF files and
submitted to the Mascot search engine (version: 2.4.1) and
compared to mammalian entries in the SwissProt and NCBInr
databases. The data search parameters were as follows: two
missed trypsin cleavage sites; peptide tolerance, ±0.3 Da;
number of C13¼1; peptide charge, 1+, 2 + and 3 + ions.
Carbamidomethyl cysteine was specified as a fixed modifi-
cation, and oxidised methionine and deamidated asparagine
and glutamine residues were specified as variable modifica-
tions. Individual ions Mascot scores above 50 indicated
identity or extensive homology. Only protein identifications
with probability-based protein family Mascot MOWSE
scores above the significant threshold of 450 (p50.05)
were accepted. After mass spectrometric identification,
315 proteins were classified manually using the UniProt
(http://www.uniprot.org/) database, considering homologous
proteins and further literature information. For many pro-
teins, assigning a definitive cellular compartment and/or
function was a difficult task because of the limitations in
accurate predictions and lack of experimental evidence. Also,
many proteins may actually reside in multiple cellular
compartments. To assign identified proteins to specific
organelles, the references to subcellular localisations in the
DOI: 10.3109/1354750X.2015.1130191 Membrane biomarkers in chondrocytes 575
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UniProt database, as well as gene ontology (GO) annotations
were used.
Validation of selected membrane proteins by western
blotting
Hydrophobic and hydrophilic protein samples were loaded
onto Mini-Protean 3 gels. Approximately 20 mg protein per
lane was separated by 7.5% SDS–PAGE gel for immuno-
logical detection of selected proteins. Proteins were trans-
ferred to PVDF membranes (Immun-Blot PVDF
Membrane, Bio-Rad). After blocking in 5% non-fat dry
milk in PBST, membranes were incubated with the anti-Na+,
K+-ATPase primary antibody (diluted 1:100) in blocking
solution at 4 C overnight, with gentle rotation. Membranes
were then incubated with the secondary antibody (anti-mouse
labelled polymer HRP, DakoCytomation, 1:1000 dilution) in
blocking solution at room temperature for 1 h. Membranes
were developed by enhanced chemiluminescence reaction
(Amersham) according to the instructions of the manufacturer
and using auto-radiographic films (Hyperfilm, Amersham).
Films were scanned on a calibrated densitometer (Bio-Rad
GS800) operated by Quantity One version 4.4.1 software
(Bio-Rad). Optical density of bands was determined
using ImageJ version 1.47 (ImageJ, Bethesda, MD; http://
imagej.nih.gov/ij); data were normalised to the value detect-
able in the hydrophilic fraction.
Results
Triton X-114 phase separation efficiently enriches
membrane proteins from primary chondrocyte
cultures
To confirm whether the Triton X-114 phase separation
method was able to efficiently extract and enrich lipid-soluble
membrane proteins from primary articular chondrocytes
cultured in vitro, equal amounts of proteins (25 mg) from the
hydrophobic and the hydrophilic fractions were loaded onto
polyacrylamide gels. Following SDS–PAGE and silver
staining, protein bands with clearly different patterns
appeared in the gels with several strong bands present in
the hydrophobic fraction only (Figure 2A). To validate the
effectiveness of the Triton X-114 extraction method, western
blot experiments were performed on both fractions to probe
for the presence and relative abundance of a membrane-bound
Na+, K+-ATPase. As seen in Figure 2B, the band for this
protein in the hydrophobic pool was more than 2.6-fold
stronger than that in the hydrophilic pool, demonstrating that
lipid-soluble proteins were extracted and enriched in the
hydrophobic fraction.
To investigate the protein content of the two fractions,
trypsin-digested protein fractions were analysed by nanoLC-
MS/MS using Bruker Easy-nanoLC chromatography and a
Bruker amaZon ion trap instrument with shotgun proteomics
methodologies. A total of 315 unique proteins were reliably
(p50.05) identified in this study; 208 proteins were detected
in the hydrophobic fraction and 192 proteins in the hydro-
philic fraction, with 73 (23%) proteins present in both
fractions. According to the subcellular localisation data in
the UniProt database entries and gene ontology (GO)
annotations, in the hydrophobic pool 115 proteins (55%)
were membrane proteins and only the remaining 93 proteins
(45%) were non-membrane proteins. In contrast, only 38
proteins (20%) were listed as membrane proteins in the
hydrophilic fraction, and the other 154 proteins (80%) were
non-membrane proteins (Figure 2C). Based on the distribu-
tion of membrane versus non-membrane proteins in the two
fractions, using the Triton X-114 phase separation method, we
successfully extracted and enriched membrane proteins in
lysates of primary articular chondrocytes.
Further analysis of the hydrophobic pool reveals
various types of membrane proteins
Proteins identified in the hydrophobic fraction were further
analysed according to subcellular localisation based on gene
ontology (GO) annotation data in the UniProt database entries
(Figure 3). Of the 115 membrane proteins in this pool, PM
localisation was indicated for 64 proteins (56%), and the other
51 proteins (44%) were localised in organellar membranes.
The PM proteins were further subdivided according to their
main functions (Table 1). Eighteen proteins (28%) were
transporters or involved in membrane/vesicle traffic; 11 and
10 proteins (17 and 16%) were adhesion molecules and
proteins with enzyme functions, respectively; 15 proteins
(23%) were receptors, and the remaining 10 PM proteins
(16%) could not be assigned to any of the previous groups or
their function was unknown.
The membrane proteins with other organellar distribu-
tions were also subdivided according to their subcellular
localisations (Table 2). The majority (23 proteins; 45%)
were localised in the membrane of the Golgi complex or
the endoplasmic reticulum; 13 proteins (25%) were
localised to exosome/lysosome/endosome/other vesicular
membranes; another big portion (11 proteins; 22%) were
mitochondrial membrane proteins; two proteins (4%) were
nuclear membrane proteins; and the remaining two proteins
(4%) were ambiguous in terms of specific subcellular
localisation.
The majority of the non-membrane proteins in the
hydrophobic pool were cytoplasmic/cytoskeletal proteins
(46 proteins; 50%) and secreted (extracellular) proteins (19
entries; 20%). Other subcellular localisations included the
lysosome/endosome (4 proteins; 4%), the mitochondrion
(1 protein; 1%), the Golgi complex or the endoplasmic
reticulum lumen (8 proteins; 9%), the nucleus (10 proteins;
11%), and the remaining five proteins were either contamin-
ants or their subcellular localisation was ambiguous (5%;
Figure 4 and Table 3).
The hydrophilic pool contains proteins with different
solubility and subcellular distribution
The Triton X-114 phase separation technique effectively
extracted and enriched lipid-soluble membrane proteins in the
hydrophobic phase, and left comparably few membrane
proteins (only 20%) in the hydrophilic fraction (Figure 2C).
As in the case of the hydrophobic fraction, the majority of the
38 lipid-soluble membrane proteins were localised in the PM
(25 proteins; 66%), whilst the others were localised in various
576 C. Matta et al. Biomarkers, 2015; 20(8): 572–589
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organellar membranes (Golgi complex/endoplasmic reticulum
membrane, 16%; mitochondrial membrane, 8%; nuclear
membrane, 2%; Figure 5 and Table 4).
Taken together, we have identified 78 unique PM proteins
in equine articular chondrocytes in this work. Among them,
32 proteins possessed receptor/adhesion functions; the most
important ones are the cluster of differentiation (CD) proteins
and integrins. Furthermore, 21 PM proteins with transporter
functions were detected in articular chondrocytes (Tables 1
and 4).
The non-membrane protein complement in the hydrophilic
fraction comprised 154 proteins, the majority of which (77
proteins; 50%) were cytoplasmic/cytoskeletal proteins. Also
in good correlation with the non-membrane protein distribu-
tion observed in the hydrophobic samples, the secreted
(extracellular) and the nuclear proteins were the second and
third largest groups in this fraction (23 proteins, 15%; and 22
proteins, 14%, respectively). Other subcellular localisations
included the lysosome/endosome (5 proteins; 3%), the
mitochondrion (6 proteins; 4%), the Golgi complex or the
endoplasmic reticulum lumen (13 proteins; 9%), and the
remaining eight proteins were either contaminants or their
subcellular localisation was not determined (5%; Figure 5 and
Table 5).
Discussion
The application of mass spectrometry (MS) has recently
become an important tool in cartilage biology as it offers
numerous advantages over more conventional biochemical
approaches such as western blotting. To date, a number of
proteomic studies have been performed on cartilage tissue and
on chondrocytes, confirming that this analytical tool is
particularly suitable for high-throughput and large-scale
analysis of the protein complement in health and disease
[reviewed in Hsueh et al. (2014) and Williams et al. (2011)].
The first proteomic study carried out on normal human knee
articular chondrocyte cultures aimed at creating a two-
dimensional gel electrophoresis (2-DE) reference map and
generated 93 unique protein identities (Ruiz-Romero et al.,
2005). A 1-D SDS–PAGE approach combined with MS/MS
resulted in the identification of over 100 different proteins
Figure 2. Validation of the efficacy of the
Triton X-114 phase separation method. (A)
Distribution of protein bands in the hydro-
phobic (1) and hydrophilic (2) fractions
following phase partitioning in total lysates
from primary equine articular chondrocyte
cultures. After SDS–PAGE, protein bands
were visualised using silver staining (M,
molecular weight marker). Representative gel
image. (B) Western blot experiment per-
formed on both hydrophobic and hydrophilic
fractions to probe for the presence and
relative abundance of the membrane-bound
Na+, K+-ATPase. Numbers below bands
represent integrated densities determined by
ImageJ freeware. Representative image. (C).
The relative distribution of identified proteins
following analysis by nanoLC-MS/MS based
on their solubility in both hydrophobic and
hydrophilic fractions. Numbers outside pie
charts represent the actual numbers of pro-
teins identified in each subgroup.
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from human knee cartilage supernatants (Garcia et al., 2006).
In the first large-scale MS analysis of human articular
cartilage, which was designed to extract both extracellular and
intracellular proteins from samples depleted of highly abun-
dant ECM proteins such as collagens and aggrecan to allow
the detection of less abundant proteins, a total number of 814
distinct proteins were identified (Wu et al., 2007). In a more
recent study, the proteome of articular chondrocytes from
healthy and OA patients using high resolution label-free MS
was analysed, leading to the identification of 2400 proteins
(Tsolis et al., 2015).
Despite these studies and the impressive number of
proteins identified, our knowledge about the proteome of
cartilage and its resident cell, the chondrocyte, can still be
improved. One significant drawback is that at least in some of
the studies the identified proteins have not been properly
analysed in terms of subcellular locations and/or functions. In
addition, the majority of proteins identified in these studies
were located in the ECM because of their high abundance
relative to cellular proteins in chondrocytes. More specific-
ally, the ‘‘hidden’’ proteome, which comprises low abundance
proteins and/or is not accessible by standard methods, is still
poorly characterised. In a study that combined extensive pre-
fractionation followed by electrospray ionisation mass spec-
trometry (ESI-MS/MS), 779 unique proteins expressed by
cultured chondrocytes were identified, of which 203 were
annotated to the membrane (Lambrecht et al., 2010).
However, the authors did not carry out a detailed analysis
with respect to specific subcellular location and/or function of
the identified membrane proteins, making further data
interpretation attempts challenging.
Therefore, the aim of this study was to extend the current
knowledge of the chondrocyte proteome by using the Triton
X-114 phase separation technique to discover the membrane
Figure 3. Subcellular distribution of the
identified membrane proteins in the hydro-
phobic fraction. PM proteins were further
classified according to their main function
based on GO annotations. Numbers outside
pie charts represent the actual numbers of
proteins identified in each subgroup.
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Table 1. Functional classification of PM proteins in the hydrophobic fraction identified in equine articular chondrocytes based on GO annotations.
# Name
Accession
No.*
Mascot
score
Seq.
coverage
(%)
No. of
matched
peptides
Transporters, membrane/vesicle traffic
1 Voltage-dependent anion-selective channel protein 1 VDAC1 383 36.7 8
2 Voltage-dependent anion-selective channel protein 2 VDAC2 313 25.9 6
3 Voltage-dependent anion-selective channel protein 3 VDAC3 139 12.0 3
4 Ras-related protein Rab-5B RAB5B 134 15.8 3
5 Ras-related protein Rab-5C RAB5C 164 16.2 3
6 Ras-related protein Rab-8A RAB8A 135 17.4 3
7 Ras-related protein Rab-8B RAB8B 145 17.4 3
8 Ras-related protein Rab-9A RAB9A 61 10.4 1
9 Membrane-associated progesterone receptor component 2 PGRC2 178 17.0 4
10 Annexin A1 ANXA1 125 9.2 2
11 Dolichyl-diphosphooligosaccharide–protein glycosyltransferase 48 kDa subunit OST48 86 4.6 2
12 Solute carrier family 2, facilitated glucose transporter member 1 GTR1 118 6.3 3
13 Solute carrier family 2, facilitated glucose transporter member 3 GTR3 74 4.0 3
14 Caveolin-1 CAV1 69 11.8 1
15 Monocarboxylate transporter 1 MOT1 75 2.4 1
16 PREDICTED: Melanotransferrin (CD228 antigen) MFI2 64 4.5 2
17 PREDICTED: Equilibrative nucleoside transporter 1 isoform X1 SCL29A1 67 5.5 2
18 PREDICTED: Synaptosomal-associated protein 23 SNAP23 57 11.4 1
Adhesion molecules
1 Integrin alpha-5 (CD49e antigen, Fibronectin receptor alpha subunit; fragment) ITA5 97 6.5 2
2 Integrin alpha-V (CD51 antigen, Vitronectin receptor alpha subunit) ITAV 84 3.2 3
3 Integrin beta-1 (CD29 antigen, Fibronectin receptor beta subunit) ITB1 753 22.4 16
4 Thrombospondin-1 TSP1 435 9.7 9
5 RA175 (Cell adhesion molecule 1) CADM1 58 5.5 1
6 CD151 antigen (Tetraspanin-24) CD151 79 5.9 2
7 CD166 antigen (ALCAM, Fragment) CD166 125 8.4 3
8 CD107 antigen (Lysosome-associated membrane glycoprotein) LAMP2 53 2.0 2
9 PREDICTED: CD9 antigen (tetraspanin-29) CD9 88 10.4 2
10 PREDICTED: integrin alpha-3 isoform 2 (CD49c antigen) ITA3 60 1.2 1
11 PREDICTED: integrin beta-3 (CD61 antigen) ITB3 57 0.8 1
Receptors
1 Protein S100-A6 (Calcyclin) S10A6 277 53.3 4
2 CD44 antigen (Hyaluronan receptor) CD44 260 15.3 5
3 CD63 antigen (Tetraspanin-30) CD63 55 2.5 1
4 CD81 antigen (Tetraspanin-28) CD81 54 8.5 1
5 Cofilin-1 COF1 234 39.8 5
6 Myristoylated alanine-rich C-kinase substrate MARCS 172 9.0 3
7 Cell division control protein 42 homologue CDC42 154 6.5 3
8 CD71 antigen (Transferrin receptor protein 1) TFR1 64 1.7 1
9 PREDICTED: Thy-1 membrane glycoprotein (CD90 antigen) THY1 152 21.1 3
10 Basigin (CD147 antigen) precursor BSG 100 13.7 3
11 PREDICTED: disintegrin and metalloproteinase domain-containing protein 9 isoform 1 ADAM9 83 1.7 1
12 P48 (Cytokine receptor-like factor 3) CRLF3 80 6.8 2
13 Membrane steroid binding protein gij7689365 191 29.2 4
14 Mannose receptor, C type 2 MRC2 69 0.9 1
15 Lactadherin MFGM 66 2.7 1
Enzymes
1 Protein disulfide-isomerase PDIA1 320 11.8 5
2 Alpha-enolase ENOA 295 24.4 7
3 CD73 antigen (5’-nucleotidase) 5NTD 160 12.0 5
4 Ras-related protein Rap-1b RAP1B 146 19.0 3
5 Prolyl endopeptidase FAP SEPR 130 5.3 3
6 Transforming protein RhoA RHOA 146 24.9 4
7 TRAF2 and NCK-interacting protein kinase TNIK 61 0.6 1
8 Thioredoxin-related transmembrane protein 1 TMX1 67 4.3 1
9 Rho GTPase-activating protein 21 RHG21 56 0.4 1
10 PREDICTED: adipocyte plasma membrane-associated protein isoform X1 APMAP 62 3.0 1
Miscellaneous
1 Brain acid soluble protein 1 BASP1 223 21.1 4
2 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 GBG12 98 56.9 3
3 Receptor expression-enhancing protein 5 REEP5 86 11.6 2
4 CD276 antigen CD276 55 10.8 2
5 Annexin A5 ANXA5 54 3.8 1
6 Tuberin TSC2 54 0.4 1
7 PREDICTED: Tetraspanin-6 isoform X1 TSPAN6 105 7.8 2
8 PREDICTED: Matrix-remodeling-associated protein 7 MXRA7 79 20.3 1
9 PREDICTED: Protein lifeguard 3 TMBIM1 77 4.5 1
10 PREDICTED: Proteolipid protein 2 PLP2 72 18.4 2
*UniProt IDs are shown where available. In other cases, NCBInr accession numbers are shown.
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subproteome (the membranome). We have chosen to use
equine articular chondrocytes in this study, for the horse is
widely involved in occupational/sports activities and con-
sidered as an excellent animal model for human joint
diseases (Aigner et al., 2010) and yet, current knowledge is
limited and relates to only the protein complement of equine
chondrocytes. The unique features of our study are as
follows. First, to the best of our knowledge, this is the first
application of LC-MS/MS proteomics to study the mem-
brane protein complement of cultured articular chondrocytes.
Second, a large proportion (133 proteins; 42%) of the 315
proteins identified in this work consisted of membrane
Table 2. Subcellular distribution of membrane proteins in the hydrophobic pool identified in equine articular chondrocytes based on GO annotations.
# Name
Accession
No.*
Mascot
score
Seq.
coverage (%)
No. of matched
peptides
Exosome/lysosome/endosome/vesicle membrane
1 Ras-related protein Rab-7a RAB7A 538 60.9 10
2 Vesicle-associated membrane protein 3 VAMP3 239 38.5 3
3 Ras-related protein Rab-10 RAB10 164 22.5 4
4 14-3-3 protein theta 1433T 201 22.0 5
5 Cation-dependent mannose-6-phosphate receptor MPRD 150 13.3 3
6 Syntaxin-7 STX7 144 19.9 5
7 Ras-related protein Rab-11B RB11B 176 14.2 3
8 Ras-related protein Rab-14 RAB14 128 15.3 3
9 Vesicle-associated membrane protein 5 VAMP5 54 11.2 1
10 Lysosome membrane protein 2 SCRB2 115 2.7 1
11 Charged multivesicular body protein 6 CHMP6 51 6.5 1
12 PRA1 family protein 2 PRAF2 89 16.3 2
13 PREDICTED: glucosylceramidase isoform X2 GLCM 88 4.9 2
Golgi/ER membrane
1 Ras-related protein Rab-1A RAB1A 301 35.6 6
2 Ras-related protein Rab-1B RAB1B 266 25.9 5
3 Ras-related protein Rab-2A RAB2A 213 24.5 4
4 Transmembrane emp24 domain-containing protein 2 (Fragment) TMED2 83 10.7 2
5 Transmembrane emp24 domain-containing protein 5 TMED5 57 5.3 1
6 Transmembrane emp24 domain-containing protein 9 TMED9 116 14.9 3
7 Transmembrane emp24 domain-containing protein 10 TMEDA 228 22.4 5
8 Membrane-associated progesterone receptor component 1 PGRC1 149 11.8 2
9 Membrane-associated progesterone receptor component 2 PGRC2 178 17.0 4
10 Transmembrane emp24 domain-containing protein 4 TMED4 120 12.3 2
11 78 kDa glucose-regulated protein GRP78 155 5.5 3
12 Translocon-associated protein subunit delta SSRD 110 17.3 2
13 Surfeit locus protein 4 SURF4 93 8.2 2
14 Vesicular integral-membrane protein VIP36 LMAN2 58 3.4 1
15 Calnexin CALX 78 2.2 1
16 B-cell receptor-associated protein 31 BAP31 85 8.1 2
17 Eukaryotic translation initiation factor 5A-1 IF5A1 53 10.4 2
18 Vesicle-associated membrane protein-associated protein A VAPA 83 4.8 1
19 Vesicle-trafficking protein SEC22b SC22B 53 5.6 1
20 PREDICTED: PRA1 family protein 3 PRAF3 89 16.0 3
21 lanosterol 14-alpha demethylase CP51A 72 2.4 1
22 PREDICTED: golgin subfamily B member 1 GOGA1 69 0.4 1
23 PREDICTED: NADH-cytochrome b5 reductase 3-like isoform 1 gij338721361 62 4.7 1
Mitochondrial membrane
1 Cytochrome c oxidase subunit 5A, mitochondrial COX5A 197 30.9 4
2 ATP synthase subunit beta, mitochondrial ATPB 235 16.7 7
3 ATP synthase subunit alpha, mitochondrial ATPA 144 6.3 3
4 ATP synthase subunit delta, mitochondrial ATPD 90 8.3 1
5 Apoptosis regulator BAX BAX 70 5.7 1
6 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial (Fragment) COX41 59 10.3 1
7 Carbamoyl-phosphate synthase [ammonia], mitochondrial CPSM 65 1.2 1
8 prohibitin-2 PHB2 63 4.0 1
9 Cytochrome c oxidase subunit 5B, mitochondrial COX5B 61 3.3 2
10 cytochrome oxidase subunit 2 COX2 74 3.1 1
11 PREDICTED: mitochondrial fission 1 protein-like gij558166747 58 10.5 1
Nuclear membrane
1 PREDICTED: nesprin-1 SYNE1 73 0.1 1
2 PREDICTED: transmembrane protein 109 isoform X1 TMEM109 60 4.9 1
Miscellaneous
1 Peptidyl-prolyl cis–trans isomerase A PPIA 241 43.3 5
2 PREDICTED: cell cycle progression protein 1 isoform X1 CCPG1 65 1.6 2
*UniProt IDs are shown where available. In other cases, NCBInr accession numbers are shown.
580 C. Matta et al. Biomarkers, 2015; 20(8): 572–589
D
ow
nl
oa
de
d 
by
 [1
76
.74
.24
2.4
9]
 at
 02
:50
 30
 M
arc
h 2
01
6 
proteins, and for some of these only ambiguous data were
available in chondrocytes [e.g. CD276, S100-A6 (calcyclin),
VDACs]. The proportion of membrane proteins was even
higher in the hydrophobic phase (55%). As far as the
proportion of membrane proteins is concerned, our results
are in a good agreement with those reported elsewhere
(Hansson et al., 2010). The aim of that study was to
characterise the human pancreatic islet membrane proteome
by evaluating five different extraction procedures; while the
proportion of membrane proteins in the total extracts was
35%, a considerably higher proportion (61%) of membrane
proteins was identified following the use of membrane
protein-enriching methods. It is also worth noting that the
choice of method for extraction of membrane proteins had a
strong influence on the number and identity of proteins
detected in that analysis, and the hydrophobic phase of
Triton X-114 phase separation was found to be the most
efficient extraction method (Hansson et al., 2010). These
results also underpin that appropriate sample preparation and
pre-fractionation methods can increase the amount of
identified proteins with specific properties in the MS/MS
analysis of proteins in complex biological samples. It was for
that reason that we used the Triton X-114 phase separation
method in this study.
Although a detailed description of the proteins identified in
the chondrocyte membranome is beyond the scope of this
article, a few important protein classes merit comment due to
their potential involvement in chondrocyte homeostasis. We
therefore restrict discussing our results to certain protein
groups localised in the PM.
CD antigens and integrins
Cluster of differentiation (CD) proteins are four hydrophobic
domain-containing cell surface membrane glycoproteins that
mediate a range of cellular processes including development,
differentiation, activation, growth and motility. Composed of
alpha and beta subunits, integrins are integral PM receptors
that mediate attachment between a cell and its surroundings.
They transduce information from the ECM to the cell and
integrin-mediated signalling pathways influence cell shape,
mobility, differentiation and the cell cycle. The integrins
identified in this study (integrin beta-1 [CD29], integrin
alpha-5 [CD49e], integrin alpha-V [CD51], integrin alpha-3
[CD49c] and integrin beta-3 [CD61]) are in a complete
agreement with what has been published earlier (Mobasheri
et al., 2002a; Shakibaei et al., 2008; Woods et al., 1994). Our
data also confirm reports on CD antigen expression in
articular chondrocytes (Diaz-Romero et al., 2005). We found
that equine articular chondrocytes express tetraspanins (CD9
[tetraspanin-19], CD63 [tetraspanin-30], CD81 [tetraspanin-
28] and CD151 [tetraspanin-24]); CD44 (hyaluronan recep-
tor); CD71 (transferrin receptor); CD90 (Thy-1); and CD166
(ALCAM). CD73, an ecto-50-nucleotidase, which plays a
crucial role in extracellular adenosine generation, has been
reported to be involved in mechanotransduction pathways
following cyclic compressive stimulation (Ode et al., 2013).
CD107 (LAMP) expression has been recently reported in
murine growth plate cartilage and cartilaginous nodules in
embryonic limb bud-derived micromass cultures
(Hatakeyama et al., 2014). CD147 (basigin; also known as
extracellular matrix metalloproteinase inducer) is known to be
extensively expressed by chondrocytes both in normal and OA
cartilage (Orazizadeh & Salter, 2008). CD228 (melanotrans-
ferrin) has also long been known to facilitate the differenti-
ation of prechondrogenic cells (Suardita et al., 2002). While
CD276 has not been identified earlier in chondrocytes, it is
known to be expressed in undifferentiated mesenchymal stem
cells derived from Wharton’s jelly (WJ-MSCs), even after
osteogenic, adipogenic and chondrogenic differentiation (La
Rocca et al., 2013).
S100 proteins
Of particular interest is protein S100-A6 (calcyclin) expres-
sion in equine articular chondrocytes. The S100 family of
proteins consists of 24 members, which show cell-specific
expression patterns and are involved in a wide range of
cellular processes including proliferation, differentiation,
apoptosis, Ca2+ homeostasis, energy metabolism, inflamma-
tion and migration/invasion through interactions with a
variety of target proteins ranging from enzymes, cytoskeletal
Figure 4. Subcellular localisation of the identified non-membrane
proteins in the hydrophobic fraction based on GO annotations.
Numbers outside pie chart represent the actual numbers of proteins
identified in each subgroup.
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Table 3. Subcellular distribution of non-membrane proteins in the hydrophobic pool identified in equine articular chondrocytes based on GO
annotations.
# Name
Accession
No.*
Mascot
score
Seq.
coverage
(%)
No. of
matched
peptides
Secreted (extracellular)/exosome
1 Alpha-2-macroglobulin A2MG 914 15.8 19
2 Transgelin-2 TAGL2 426 47.7 9
3 Apolipoprotein D APOD 188 24.3 6
4 Alpha-1-antiproteinase (Serpin A1, antitrypsin) A1AT 220 9.4 5
5 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 GBB1 90 6.2 2
6 Annexin A2 ANXA2 83 7.7 2
7 Guanine nucleotide-binding protein subunit beta-4 GBB4 119 9.7 3
8 Galectin-1 LEG1 119 16.3 2
9 Pancreatic trypsin inhibitor BPT1 52 13.0 1
10 Transthyretin TTHY 95 19.0 2
11 SPARC SPRC 190 25.3 5
12 Alpha-S1-casein CASA1 72 10.3 2
13 Triosephosphate isomerase TPIS 214 21.3 4
14 Hemopexin HEMO 55 3.5 2
15 Apolipoprotein E APOE 54 6.5 2
16 Hypothetical protein PANDA_010395 (lipocalin) gij281339160 152 5.9 1
17 PREDICTED: cell growth regulator with EF hand domain protein 1 isoformX1 gij149727690 111 14.1 3
18 Complement component C4 CO4 63 11.6 1
19 PREDICTED: ovostatin-like gij344278152 57 1.1 1
Cytoplasm/cytoskeleton
1 Actin, cytoplasmic 1 ACTB 610 41.1 14
2 Tropomyosin alpha-4 chain TPM4 538 32.7 10
3 Myosin light polypeptide 6 MYL6 337 52.3 8
4 60S acidic ribosomal protein P2 RLA2 334 60.0 5
5 Tropomyosin alpha-1 chain TPM1 339 21.5 7
6 Tropomyosin beta chain TPM2 319 18.0 6
7 Glyceraldehyde-3-phosphate dehydrogenase G3P 271 15.9 4
8 Tropomyosin alpha-3 chain TPM3 298 21.4 6
9 Tubulin alpha-1B chain TBA1B 381 19.1 7
10 Transgelin TAGL 136 16.4 3
11 L-lactate dehydrogenase A chain LDHA 217 13.3 4
12 Pyruvate kinase PKM KPYM 186 12.6 5
13 Tubulin alpha-1A chain TBA1A 168 12.2 4
14 Heat shock protein beta-1 (hsp25, hsp27) HSPB1 209 22.5 5
15 Peroxiredoxin-1 PRDX1 217 27.1 6
16 14-3-3 protein zeta/delta 1433Z 74 19.2 3
17 Tubulin beta-5 chain TBB5 122 9.9 3
18 Profilin-1 PROF1 112 24.3 4
19 Fructose-bisphosphate aldolase A ALDOA 178 13.7 3
20 Hsc70-interacting protein F10A1 63 6.8 2
21 14-3-3 protein epsilon 1433E 57 11.4 2
22 Phosphoglycerate kinase 1 PGK1 83 6.7 2
23 Myosin-9 MYH9 100 0.6 1
24 Far upstream element-binding protein 2 FUBP2 103 4.6 3
25 Caldesmon CALD1 82 3.9 2
26 14-3-3 protein beta/alpha 1433B 81 11.8 2
27 Guanine nucleotide-binding protein G(i) subunit alpha-2 GNAI2 77 7.9 2
28 60S acidic ribosomal protein P1 RLA1 64 14.0 1
29 40S ribosomal protein S12 RS12 63 19.7 2
30 Nuclease-sensitive element-binding protein 1 YBOX1 61 4.6 1
31 Calmodulin CALM 59 22.1 2
32 Elongation factor 1-alpha 1 EF1A1 56 5.0 2
33 Heat shock cognate 71 kDa protein HSP7C 134 6.3 3
34 Metallothionein-1A MT1A 52 19.7 1
35 Protein S100-A1 S10A1 50 16.0 1
36 PREDICTED: protein S100-A11 gij149751468 160 27.0 3
37 A-kinase anchor protein 9 AKAP9 82 0.3 1
38 PREDICTED: plasminogen activator inhibitor 1 RNA-binding protein isoform 1 gij345800374 81 4.1 1
39 PREDICTED: peroxiredoxin-6 gij149707887 80 17.9 3
40 hsp70A1 gij193983 79 2.7 2
41 40S ribosomal protein S28 RPS28 79 30.4 2
42 PREDICTED: phosphatidylethanolamine-binding protein 1 gij149720563 74 18.7 3
43 G-protein beta subunit gij51116 72 17.1 2
44 phosphoglycerate mutase gij189868 59 9.5 2
45 Stathmin STMN1 59 15.1 2
46 Tropomyosin 3, gamma isoform 19-like protein gij528766928 268 18.6 7
(continued )
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subunits, receptors, transcription factors and nucleic acids
[reviewed in Donato et al. (2013)]. In particular, S100-A6
may function as a Ca2+ sensor and modulator, contributing to
Ca2+ signalling pathways. It is also implicated in cell
proliferation and cytoskeletal dynamics, and known to have
a potential role in cell responses to different stressors.
Calcyclin was reported to be significantly upregulated in
serially passaged adipose tissue-derived MSCs (Capra et al.,
2012), which may correspond to previous data suggesting that
it is frequently upregulated during proliferation and differen-
tiation and it is induced by different growth factors. There are
only sporadic data available relating to S100-A6 expression in
chondrocytes. Its mRNA transcript has been shown to be
downregulated following chondrogenic induction by BMP4 in
ATDC5 cells, and it has also been identified in one of the
chondrocyte proteome studies discussed earlier (Lambrecht
et al., 2010).
Other S100 proteins identified in this study include S100-
A1 and S100-A11 (Tables 3 and 5). S100-A1 is localised in
the cytoplasm where it is associated with cytoskeletal
components and mitochondria. It can influence Ca2+
handling in cultured ventricular cardiomyocytes through
interaction with the sarcoplasmic reticulum Ca2+-ATPase
and RyR2; it also modulates CaV1 channel currents in a PKA-
dependent manner. S100-A1 also regulates energy metabol-
ism by stimulating fructose-1,6-biphosphate aldolase and
inhibiting phosphoglucomutase and glycogen phosphorylase
(Donato et al., 2013). Also localised in the cytoplasm, S100-
A11 is reported to modulate cell growth via binding either to
nucleolin or Rad54B (Donato et al., 2013). In particular,
S100-A11 can activate the p38 MAPK pathway to accelerate
chondrocyte hypertrophy and ECM catabolism that may
promote OA progression (Cecil & Terkeltaub, 2008). Both
S100-A1 and S100-A11 have been reported to be expressed
and functional in chondrocytes (Donato et al., 2013;
Patti et al., 1999), and both proteins were identified in a
previous MS study (Lambrecht et al., 2010).
Transporters
Ion channels and transporters are essential components of
chondrocytes that control the movement of ions and other
small molecules across the PM. An increasing number of
studies have reported the presence of an ever-expanding list of
Table 3. Continued
# Name
Accession
No.*
Mascot
score
Seq.
coverage
(%)
No. of
matched
peptides
Lysosome/melanosome/endosome
1 Cathepsin D CATD 218 15.6 7
2 Prosaposin SAP 184 6.5 4
3 Cathepsin K CATK 56 5.2 2
4 CLN2 protein (tripeptidyl peptidase 1) TPP1 64 1.8 1
Mitochondrion
1 PREDICTED: Diablo homologue, mitochondrial-like gij345323079 69 4.1 1
Golgi/ER lumen
1 Reticulocalbin-3 RCN3 252 12.2 3
2 Glucosidase 2 subunit beta GLU2B 129 4.3 2
3 Endoplasmin (hsp90beta1) ENPL 123 2.5 2
4 Glucosidase 2 subunit beta GLU2B 100 5.8 2
5 Calumenin CALU 73 10.2 2
6 Serpin H1 SERPH 73 3.6 1
7 Calreticulin CALR 65 3.1 1
8 Endoplasmic reticulum resident protein 29 ERP29 51 8.4 2
Nucleus
1 Far upstream element-binding protein 1 FUBP1 237 14.4 7
2 Prothymosin alpha PTMA 198 21.8 4
3 Neuroblast differentiation-associated protein AHNAK AHNK 166 0.8 4
4 Thioredoxin THIO 130 2.1 2
5 Coiled-coil domain-containing protein 57 CCD57 67 0.8 1
6 Small ubiquitin-related modifier 2 SUMO2 54 12.6 1
7 PREDICTED: zinc finger protein 764-like gij558191623 66 2.7 1
8 PREDICTED: Fanconi anaemia group C protein gij348565316 56 1.6 1
9 PREDICTED: poly [ADP-ribose] polymerase 6 isoformX1 gij545216657 206 4.9 2
10 Bromodomain adjacent to zinc finger domain protein 2A BAZ2A 198 2.7 5
Contaminants
1 Keratin, type II cytoskeletal 1 K2C1 592 21.4 12
2 Serum albumin ALBU 195 7.7 4
3 Trypsin TRYP 75 7.8 2
Miscellaneous
1 PREDICTED: leptin receptor gene-related protein-like isoform X1 gij545218045 79 11.5 1
2 Chain C, Ternary Complex Of A Calcineurin A Fragment, Calcineurin B, Fkbp12
And The Immunosuppressant Drug Fk506 (tacrolimus)
gij1942335 65 12.1 1
*UniProt IDs are shown where available. In other cases, NCBInr accession numbers are shown.
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ion channels and transporters in chondrocytes [reviewed in
Barrett-Jolley et al. (2010) and Matta et al. (2015)]. Based on
GO annotations, 21 proteins with transporter functions were
identified in the PM in this study (Tables 1 and 4). Originally
described as being localised in the outer mitochondrial
membrane (Benz, 1994), voltage-dependent anion-selective
channels (VDACs), also known as mitochondrial porins, form
the pores that allow the transport of small hydrophilic solutes
across the membrane. However, accumulating evidence
support that VDACs can also be expressed in the PM (De
Pinto et al., 2010), where they exhibit voltage-gated anion
channel activity, and its electrophysiological phenotype is that
of a maxi-chloride channel (Lewis et al., 2013). Although
VDACs have not been unequivocally reported to be expressed
and function in chondrocytes, the anion channel identified in
some previous studies was the maxi-chloride channel, which
is remarkably similar to the maxi-Cl–/VDAC channel
(Sugimoto et al., 1996; Tsuga et al., 2002). Although all
three VDAC proteins were identified in chondrocytes in our
experiments and also by others (Lambrecht et al., 2010),
further studies will need to functionally investigate the
physiological and pathophysiological roles of these trans-
porters in the chondrocyte PM.
The chloride intracellular channel (CLIC) proteins possess
pH-dependent chloride ion channel activity. CLIC1 and
CLIC4, in addition to other members of the CLIC family,
are often referred to as ‘‘p64-related’’ proteins, and while
they may localise to intracellular compartments (e.g. the
nucleus), they also appear to be in the PM and could serve a
role in secretion (Lewis et al., 2013). Once again, although
the CLIC1 protein was identified in chondrocytes in this
study and by others (Lambrecht et al., 2010), its presence
and function has not been unambiguously demonstrated
earlier.
In addition to anion channels, glucose transporter (GLUT)
proteins (facilitative glucose transporter 1 and 3; GLUT 1 and
GLUT3) were also identified in our study. Glucose is a key
metabolite and a structural precursor for articular cartilage
and its transport has significant consequences for cartilage
development and functional integrity. Our results are in a
good agreement with previously published data (Mobasheri
et al., 2002b), confirming here by proteomic techniques the
expression of these two GLUT isoforms in articular
chondrocytes.
Conclusion
In summary, studying the membranome profile of equine
articular chondrocytes by LC-MS/MS following enrichment
using Triton X-114 pre-fractionation has turned out to be an
excellent approach to gain insight into proteins involved in a
wide range of membrane-bound processes such as signal
transduction, adhesion and transport of ions and other
molecules. In spite of the significant enrichment of lipid-
soluble membrane proteins in the hydrophobic phase, the
proteins that are present in an extremely low abundance in
chondrocytes such as the majority of ion channels and other
transporter molecules in the PM remained undetectable.
Although detergent-based phase partitioning enriches PM
proteins relative to total soluble proteins, the membrane
proteins in the ER, mitochondria and other organelles are also
enriched; and the abundance of proteins in the contaminating
organelles can interfere with the ability to detect PM proteins
(Zhang & Peck, 2011). To mitigate these limitations, a
Figure 5. Subcellular localisation of the
identified membrane and non-membrane
proteins in the hydrophilic fraction based on
GO annotations. Numbers outside pie charts
represent the actual numbers of proteins
identified in each subgroup.
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combination of the Triton X-114 phase separation method
with other membrane protein enrichment techniques could
also be considered.
Our study confirms some previous findings and adds
further proteins to the proteomic profile of equine articular
chondrocytes. Some of the identified proteins including the
CD276 antigen, S100-A6 (calcyclin) or VDACs have not been
unambiguously reported before to be components of articular
chondrocytes. However, there are certain limitations to this
work. First and foremost, protein identifications were some-
what aggravated by the fact that our search results listed the
same proteins several times but for different species (primar-
ily human or bovine but no horse entries), suggesting that the
protein was present in the sample and that the identification
was made by virtue of the horse protein sharing homology
with several other species. This is one of the disadvantages
when ‘‘cross species matching’’ is used to identify proteins.
Another possible disadvantage of using equine articular
chondrocytes is that there may be subtle differences between
the two species and that the entirety of our results may not be
directly applicable to human articular chondrocytes.
A more detailed and comprehensive insight into the
chondrocyte membranome is likely to make a significant
contribution to the development of novel drugs for arthritic
diseases. The development and refinement of proteomics-
based techniques will enable a better understanding of
regulatory proteins and enhance the search for new drug
targets. It may also help to discover novel cartilage disease-
specific biomarkers. Thus, our data represent a significant
addition to the comprehensive cartilage proteome database
that is essential for understanding the molecular mechanisms
underlying cartilage function and OA.
Table 4. Functional classification of PM proteins and other membrane proteins in the hydrophilic pool identified in equine articular chondrocytes
based on GO annotations.
# Name
Accession
No.*
Mascot
score
Seq. coverage
(%)
No. of matched
peptides
Function of
PM protein
Plasma membrane/surface proteins
1 Thrombospondin-1 TSP1 811 14.3 14 Adhesion
2 Protein disulfide-isomerase PDIA1 614 28.1 13 Enzyme
3 Alpha-enolase ENOA 557 32.5 11 Enzyme
4 Annexin A1 ANXA1 468 39.9 10 Transporter
5 Cofilin-1 COF1 306 38.6 5 Receptor
6 Moesin MOES 303 15.1 8 Adhesion
7 Annexin A5 ANXA5 258 19.1 6 Other (receptor)
8 Integrin beta-1 (CD29 antigen, Fibronectin receptor beta subunit) ITB1 160 6.3 4 Adhesion
9 Protein disulfide-isomerase A6 PDIA6 147 14.1 4 Enzyme
10 Protein disulfide-isomerase A4 PDIA4 109 1.9 1 Enzyme
11 Prolow-density lipoprotein receptor-related protein 1 LRP1 76 0.5 2 Receptor
12 Annexin A4 ANXA4 58 5.6 2 Other (receptor)
13 40S ribosomal protein SA (Laminin receptor) RSSA 57 4.4 1 Receptor
14 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 PLOD2 53 1.9 1 Enzyme
15 Myristoylated alanine-rich C-kinase substrate MARCS 52 4.5 1 Other
16 Cytoskeleton-associated protein 4 CKAP4 99 5.0 3 Receptor
17 Guanine nucleotide-binding protein subunit beta-2-like 1 GBLP 66 7.3 2 Other
18 Brain acid soluble protein 1 BASP1 52 5.7 1 Other
19 Talin-1 TLN1 418 3.1 8 Other (receptor)
20 PREDICTED: annexin A8 isoform X1 gij149690688 127 12.8 3 Other
21 PREDICTED: alpha-2-macroglobulin receptor-associated protein gij545213509 116 7.3 2 Other
22 PREDICTED: chloride intracellular channel protein 1 gij149732344 68 12.4 2 Transporter
23 PREDICTED: ADP/ATP translocase 2-like gij558210559 64 2.7 1 Transporter
24 PREDICTED: utrophin gij507925858 57 0.4 1 Other
25 Vacuolar protein sorting-associated protein 35 VPS35 65 1.6 1 Transporter
Exosome/lysosome/endosome/vesicle membrane
Golgi/ER membrane
1 78 kDa glucose-regulated protein GRP78 734 30.0 15
2 Peptidyl-prolyl cis-trans isomerase A PPIA 268 43.3 7
3 Peptidyl-prolyl cis-trans isomerase B PPIB 174 21.3 4
4 14-3-3 protein theta 1433T 122 13.9 3
5 Calnexin CALX 49 2.2 1
6 PREDICTED: golgin subfamily B member 1 isoform 1 gij466052157 62 0.3 1
Mitochondrial membrane
1 ATP synthase subunit beta, mitochondrial ATPB 120 4.5 2
2 ATP synthase subunit alpha, mitochondrial ATPA 89 6.1 2
3 ATP synthase subunit delta, mitochondrial ATPD 74 8.3 1
Nuclear membrane
1 Nesprin-1 SYNE1 57 0.1 1
Miscellaneous
1 DNA primase small subunit gij431914029 203 2.8 3
2 PREDICTED: calpastatin isoform X5 gij545185308 69 3.4 2
3 CD209 antigen-like protein C C209C 54 3.4 1
*UniProt IDs are shown where available. In other cases, NCBInr accession numbers are shown.
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Table 5. Functional classification of non-membrane proteins in the hydrophilic pool identified in equine articular chondrocytes based on GO
annotations.
# Name
Accession
No.*
Mascot
score
Seq.
coverage (%)
No. of
matched
peptides
Secreted (extracellular), exosome
1 Alpha-2-macroglobulin A2MG 2098 37.0 45
2 Transgelin-2 TAGL2 475 44.2 7
3 Annexin A2 ANXA2 397 27.7 8
4 Triosephosphate isomerase TPIS 337 30.5 6
5 Hemopexin HEMO 270 17.9 7
6 Serotransferrin TRFE 268 13.1 7
7 Alpha-1-antiproteinase A1AT 254 10.3 5
8 Collagen alpha-1(I) chain CO1A1 141 1.8 2
9 Myosin regulatory light chain RLC-A MRLCA 127 22.7 3
10 Galectin-1 LEG1 109 22.2 3
11 Transthyretin TTHY 91 19.0 2
12 Macrophage migration inhibitory factor MIF 86 17.4 2
13 Complement C4 (Fragments) CO4 63 3.6 2
14 Alpha-1-inhibitor 3 A1I3 59 0.8 1
15 Pancreatic trypsin inhibitor BPT1 51 13.0 1
16 Connective tissue growth factor CTGF 98 2.9 1
17 SH3 domain-binding glutamic acid-rich-like protein SH3L1 62 7.9 1
18 Collagen alpha-5(VI) chain CO6A5 58 0.2 1
19 Thrombospondin-2 TSP2 50 1.0 1
20 PREDICTED: heat shock protein HSP 90-alpha-like, partial gij507695623 99 3.8 2
21 PREDICTED: glia-derived nexin (Serpin E2) gij344268474 60 3.0 1
22 AM2 receptor gij49942 60 0.4 2
23 Semaphorin-3G precursor gij9910362 57 1.3 1
Cytoplasm/cytoskeleton
1 Tropomyosin alpha-4 chain TPM4 902 47.6 15
2 Tropomyosin beta chain TPM2 722 31.7 12
3 Tropomyosin alpha-3 chain TPM3 639 34.7 10
4 Actin, cytoplasmic 1 ACTB 616 43.5 13
5 Tropomyosin alpha-1 chain TPM1 584 32.4 11
6 Phosphoglycerate kinase 1 PGK1 555 42.7 13
7 L-lactate dehydrogenase A chain LDHA 492 22.6 6
8 Heat shock cognate 71 kDa protein HSP7C 486 17.7 10
9 Pyruvate kinase PKM KPYM 463 23.7 10
10 14-3-3 protein epsilon 1433E 433 37.6 9
11 Fructose-bisphosphate aldolase A ALDOA 423 27.7 9
12 Filamin-A OS¼Homo sapiens FLNA 406 4.3 8
13 Tubulin alpha-1B chain TBA1B 358 20.2 7
14 Transgelin TAGL 357 41.3 8
15 Myosin-9 MYH9 351 7.2 9
16 Glyceraldehyde-3-phosphate dehydrogenase G3P 335 22.8 6
17 14-3-3 protein zeta/delta 1433Z 319 24.1 5
18 Tubulin beta-5 chain TBB5 310 20.7 7
19 Phosphoglycerate mutase 1 PGAM1 271 27.2 5
20 Myosin light polypeptide 6 MYL6 249 52.3 7
21 Protein SET SET 225 18.3 4
22 Elongation factor 1-alpha 1 EF1A1 222 11.3 6
23 Nuclease-sensitive element-binding protein 1 YBOX1 211 14.8 3
24 Glutathione S-transferase P GSTP1 202 20.0 3
25 Phosphatidylethanolamine-binding protein 1 PEBP1 196 26.2 3
26 Peroxiredoxin-1 PRDX1 195 28.1 5
27 Profilin-1 PROF1 195 40.7 6
28 Alpha-actinin-4 ACTN4 193 6.0 5
29 L-lactate dehydrogenase B chain LDHB 188 9.9 3
30 Caldesmon CALD1 182 5.7 5
31 14-3-3 protein beta/alpha 1433B 174 18.3 4
32 Stathmin STMN1 159 37.6 5
33 LIM and SH3 domain protein 1 LASP1 153 13.7 3
34 Elongation factor 2 EF2 147 4.7 4
35 L-lactate dehydrogenase C chain LDHC 144 7.2 3
36 Heat shock 70 kDa protein 1A HS71A 138 5.3 3
37 Heat shock protein HSP 90-beta HS90B 128 4.7 3
38 14-3-3 protein gamma 1433G 112 6.1 2
39 Ferritin light chain FRIL 109 16.0 2
40 Vinculin VINC 107 2.5 2
41 Heat shock protein HSP 90-alpha HS90A 100 4.9 3
(continued )
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Table 5. Continued
# Name
Accession
No.*
Mascot
score
Seq.
coverage (%)
No. of
matched
peptides
42 Calmodulin CALM 97 33.6 4
43 Centromere protein F CENPF 96 0.2 1
44 Nascent polypeptide-associated complex subunit alpha, muscle-specific form NACAM 95 0.7 1
45 Ubiquitin UBIQ 92 32.9 2
46 Peroxiredoxin-4 PRDX4 91 11.8 3
47 Peroxiredoxin-6 PRDX6 89 10.3 2
48 Titin TITIN 81 0.0 2
49 Plastin-3 PLST 77 4.9 2
50 Nucleoside diphosphate kinase B NDKB 69 17.1 2
51 40S ribosomal protein S28 RS28 69 17.4 1
52 Eukaryotic translation initiation factor 4B IF4B 63 2.8 1
53 Hepatoma-derived growth factor HDGF 61 4.2 1
54 Rho GDP-dissociation inhibitor 1 GDIR1 60 15.2 2
55 Fuctinin-3 (Fragment) FUC3 59 84.6 2
56 Peptidyl-prolyl cis-trans isomerase FKBP1A FKB1A 59 12.0 1
57 Eukaryotic translation initiation factor 4H IF4H 55 5.2 1
58 Metallothionein-1A MT1A 55 19.7 1
59 Heterogeneous nuclear ribonucleoprotein Q HNRPQ 53 5.6 2
60 Rab GDP dissociation inhibitor alpha GDIA 53 8.5 2
61 60S ribosomal protein L22 RL22 52 8.6 1
62 40S ribosomal protein S21 RS21 103 12.0 1
63 Myosin-10 MYH10 95 2.3 3
64 40S ribosomal protein S19 RS19 81 6.9 1
65 Ran-specific GTPase-activating protein RANG 65 5.3 1
66 Peroxiredoxin-2 PRDX2 57 8.1 2
67 Plastin-2 PLSL 56 1.4 1
68 Prostaglandin E synthase 3 TEBP 50 8.1 1
69 Transitional endoplasmic reticulum ATPase TERA 50 1.6 1
70 Tropomyosin 3, gamma isoform 19-like protein gij528766928 639 27.2 12
71 Striated-muscle alpha tropomyosin gij207349 590 34.2 12
72 PREDICTED: protein S100-A11 gij149751468 148 27.0 3
73 PREDICTED: hsc70-interacting protein isoform X1 gij149743058 113 7.3 2
74 PREDICTED: ubiquitin-60S ribosomal protein L40 isoform X1 gij532055807 82 19.5 2
75 PREDICTED: 60S ribosomal protein L19-like gij532037025 63 4.7 1
76 Ribosomal protein S3, isoform CRA_f gij148684444 57 5.4 1
77 PREDICTED: dynein heavy chain 9, axonemal gij403275402 62 0.1 1
Lysosome/melanosome/endosome
1 Myosin-11 MYH11 166 2.9 4
2 Cathepsin K CATK 105 11.5 3
3 Cathepsin D CATD 91 6.8 2
4 Prosaposin SAP 81 4.6 2
5 PREDICTED: cathepsin B isoform X1 gij149698064 96 9.4 2
Mitochondrion
1 60 kDa heat shock protein, mitochondrial CH60 167 14.0 5
2 Malate dehydrogenase, mitochondrial MDHM 145 14.8 4
3 10 kDa heat shock protein, mitochondrial CH10 87 29.4 3
4 Arginase-2, mitochondrial ARGI2 67 3.4 1
5 Stress-70 protein, mitochondrial (Fragments) GRP75 53 2.4 1
6 Aspartate aminotransferase, mitochondrial AATM 67 2.8 1
Golgi/ER lumen
1 Protein disulfide-isomerase A3 PDIA3 573 27.5 14
2 Calumenin CALU 374 40.0 9
3 Serpin H1 SERPH 367 27.3 9
4 Endoplasmin ENPL 344 11.1 7
5 Calreticulin CALR 257 24.7 8
6 Reticulocalbin-3 RCN3 154 12.5 3
7 Glucosidase 2 subunit beta GLU2B 114 7.9 3
8 Endoplasmic reticulum resident protein 29 ERP29 92 11.1 3
9 Prolyl 4-hydroxylase subunit alpha-1 P4HA1 78 2.6 1
10 Proteasome-associated protein ECM29 homologue ECM29 58 0.3 1
11 Thioredoxin domain-containing protein 5 TXND5 56 2.3 1
12 PREDICTED: reticulocalbin-1-like gij334331754 72 8.2 2
13 PREDICTED: hypoxia up-regulated protein 1 gij514466500 62 2.1 1
(continued )
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